Ausgabe 6/2023
Inhalt (11 Artikel)
Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis
Hong Zeng, Jindong Dai, Dehong Cao, Minghao Wang, Jinge Zhao, Yuhao Zeng, Nanwei Xu, Yandong Xie, Haolin Liu, Hao Zeng, Guangxi Sun, Pengfei Shen
Clinical outcome in metastatic prostate cancer after primary radiotherapy
Matthias Moll, Harald Herrmann, Alexandru Zaharie, Gregor Goldner
Assessment of intrafractional prostate motion and its dosimetric impact in MRI-guided online adaptive radiotherapy with gating
Yuqing Xiong, Moritz Rabe, Lukas Nierer, Maria Kawula, Stefanie Corradini, Claus Belka, Marco Riboldi, Guillaume Landry, Christopher Kurz
Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes
Salvatore Cozzi, Sebastiano Finocchi Ghersi, Lilia Bardoscia, Masoumeh Najafi, Gladys Blandino, Emanuele Alì, Matteo Augugliaro, Federica Vigo, Maria Paola Ruggieri, Raffaele Cardano, Lucia Giaccherini, Federico Iori, Andrea Botti, Valeria Trojani, Patrizia Ciammella, Cinzia Iotti
Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial
David Krug, Detlef Imhoff, Alfred Haidenberger, Nicole Heßler, Jane Schäfer, Stefan Huttenlocher, Georgios Chatzikonstantinou, Christoph Fürweger, Ulla Ramm, Inke R. König, Felix Chun, Michael Staehler, Claus Rödel, Alexander Muacevic, Reinhard Vonthein, Jürgen Dunst, Oliver Blanck
Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
Johannes Rosenbrock, Christian Baues, Marius Kreis, Redouane Fouassi, Eren Celik, Pia Paffenholz, David Pfister, Axel Heidenreich, Simone Marnitz
Preoperative radiotherapy with concomitant chemotherapy in extremity soft tissue sarcomas: long-term results of a single center
Ugur Yilmaz, Serra Kamer, Huseyin Kaya, Dundar Sabah, Ulus Ali Sanli, Ipek Tamsel, Banu Yaman, Taner Akalin, Yavuz Anacak
Brooke–Spiegler syndrome: radiotherapy as the last resort?
Reinhart A. Sweeney, Matthias Goebeler, Michael Flentje, Rainer J. Klement
Re-Bestrahlung und Bevacizumab – wirksame Partner bei rezidiviertem Glioblastom
Clemens Seidel, Nils H. Nicolay
Präoperative Therapie beim Pankreaskarzinom: Daten der A021501-Studie
Katarzyna Paal, Thomas Brunner